A biotechnology company using a gene-editing technique called base editing, which rewrites single letters of the DNA code without cutting the strands the way traditional CRISPR does — swapping one base for another, like an A for a G, to fix disease-causing mutations. Its early work targets conditions such as sickle cell disease. Founded in 2017 by gene-editing scientists including David Liu, the company's name plays on "base" editing and the pinpoint focus of a beam.
Cavanagh Bethany JSVP, Finance and Treasurer · 2 transactions
+47%
51.2K
20.0K
—
3.2K
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -392.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.